# A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

> **NCT01897116** · PHASE1 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 8 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Hydroxychloroquine (HCQ)
- **DRUG:** Vemurafenib (VEM)

## Key facts

- **NCT ID:** NCT01897116
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2016-07-12
- **Final completion:** 2016-10-05
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2020-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01897116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01897116, "A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01897116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*